Transforming growth factor-β1 to the bone

Endocrine Reviews

Volumn 26, Issue 6, 2005, Pages 743-774

  Janssens, Katrien ^a   Ten Dijke, Peter ^b   Janssens, Sophie ^c   Van Hul, Wim ^a  

^a UNIVERSITY OF ANTWERP   (Belgium)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^c UNIVERSITY OF LAUSANNE   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; BASIC FIBROBLAST GROWTH FACTOR; BONE MORPHOGENETIC PROTEIN 2; COLONY STIMULATING FACTOR 1; ESTROGEN; GAMMA INTERFERON; GLUCOCORTICOID; INTERLEUKIN 1; INTERLEUKIN 11; INTERLEUKIN 6; PARATHYROID HORMONE; PLATELET DERIVED GROWTH FACTOR; PROSTAGLANDIN E2; RECOMBINANT TRANSFORMING GROWTH FACTOR BETA1; SOMATOMEDIN BINDING PROTEIN; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR ALPHA;

ANGIOGENESIS; BONE; BONE DISEASE; BONE METABOLISM; CELL DIFFERENTIATION; CELL MIGRATION; CELL PROLIFERATION; CELL SURVIVAL; CELL TYPE; DIAPHYSIS DYSPLASIA; EMBRYO DEVELOPMENT; HUMAN; INFLAMMATION; NONHUMAN; OSSIFICATION; OSTEOBLAST; OSTEOCLAST; OSTEOLYSIS; PATHOGENESIS; PHENOTYPE; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; TRANSGENIC MOUSE; WOUND HEALING;

ANIMALS; BONE AND BONES; BONE DEVELOPMENT; BONE RESORPTION; CELLS, CULTURED; HUMANS; OSTEOBLASTS; OSTEOCLASTS; PHENOTYPE; PROTEIN ISOFORMS; SIGNAL TRANSDUCTION; STEM CELLS; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA1;

EID: 26444506000     PISSN: 0163769X     EISSN: 0163769X     Source Type: Journal    
DOI: 10.1210/er.2004-0001     Document Type: Review

References (409)

1. Massagué J 1990 The transforming growth factor-β family. Annu Rev Cell Biol 6:597-641
2. Assoian RK, Komoriya A, Meyers CA, Miller DM, Sporn MB 1983 Transforming growth factor-β in human platelets. Identification of a major storage site, purification, and characterization. J Biol Chem 258:7155-7160
3. Seyedin SM, Thomas TC, Thompson AY, Rosen DM, Piez KA 1985 Purification and characterization of two cartilage-inducing factors from bovine demineralized bone. Proc Natl Acad Sci USA 82:2267-2271
4. Roberts AB, Lamb LC, Newton DL, Sporn MB, De Larco JE, Todaro GJ 1980 Transforming growth factors: isolation of polypeptides from virally and chemically transformed cells by acid/ethanol extraction. Proc Natl Acad Sci USA 77:3494-3498
5. Moses HL, Serra R 1996 Regulation of differentiation by TGF-β. Curr Opin Genet Dev 6:581-586
6. Massague J, Blain SW, Lo RS 2000 TGFβ signaling in growth control, cancer, and heritable disorders. Cell 103:295-309
7. Verrecchia F, Mauviel A 2002 Transforming growth factor-β signaling through the Smad pathway: role in extracellular matrix gene expression and regulation. J Invest Dermatol 118:211-215
8. Siegel PM, Massague J 2003 Cytostatic and apoptotic actions of TGF-β in homeostasis and cancer. Nat Rev Cancer 3:807-821
9. Pepper MS 1997 Transforming growth factor-β: vasculogenesis, angiogenesis, and vessel wall integrity. Cytokine Growth Factor Rev 8:21-43
10. O'Kane S, Ferguson MW 1997 Transforming growth factor βs and wound healing. Int J Biochem Cell Biol 29:63-78
11. Letterio JJ, Roberts AB 1998 Regulation of immune responses by TGF-β. Annu Rev Immunol 16:137-161
12. Gorelik L, Flavell RA 2002 Transforming growth factor-β in T-cell biology. Nat Rev Immunol 2:46-53
13. Gentry LE, Lioubin MN, Purchio AF, Marquardt H 1988 Molecular events in the processing of recombinant type 1 pre-pro-transforming growth factor β to the mature polypeptide. Mol Cell Biol 8:4162-4168
14. Gentry LE, Webb NR, Lim GJ, Brunner AM, Ranchalis JE, Twardzik DR, Lioubin MN, Marquardt H, Purchio AF 1987 Type 1 transforming growth factor : amplified expression and secretion of mature and precursor polypeptides in Chinese hamster ovary cells. Mol Cell Biol 7:3418-3427
15. Miyazono K, Olofsson A, Colosetti P, Heldin CH 1991 A role of the latent TGF-β1-binding protein in the assembly and secretion of TGF-β1. EMBO J 10:1091-1101
16. Nunes I, Gleizes PE, Metz CN, Rifkin DB 1997 Latent transforming growth factor-β binding protein domains involved in activation and transglutaminase-dependent cross-linking of latent transforming growth factor-β. J Cell Biol 136:1151-1163
17. Rifkin DB 2004 Latent TGF-β binding proteins: orchestrators of TGF-β availability. J Biol Chem 280:7409-7412
18. Hyytiainen M, Penttinen C, Keski-Oja J 2004 Latent TGF-β binding proteins: extracellular matrix association and roles in TGF-β activation. Crit Rev Clin Lab Sci 41:233-264
19. Dallas SL, Park-Snyder S, Miyazono K, Twardzik D, Mundy GR, Bonewald LF 1994 Characterization and autoregulation of latent transforming growth factor β (TGF β) complexes in osteoblast-like cell lines. Production of a latent complex lacking the latent TGF β-binding protein. J Biol Chem 269:6815-6821
20. Penttinen C, Saharinen J, Weikkolainen K, Hyytiainen M, Keski-Oja J 2002 Secretion of human latent TGF-β-binding protein-3 (LTBP-3) is dependent on co-expression of TGF-β. J Cell Sci 115:3457-3468
21. Taipale J, Koli K, Keski-Oja J 1992 Release of transforming growth factor-β 1 from the pericellular matrix of cultured fibroblasts and fibrosarcoma cells by plasmin and thrombin. J Biol Chem 267:25378-25384
22. Taipale J, Lohi J, Saarinen J, Kovanen PT, Keski-Oja J 1995 Human mast cell chymase and leukocyte elastase release latent transforming growth factor-β 1 from the extracellular matrix of cultured human epithelial and endothelial cells. J Biol Chem 270:4689-4696
23. Annes JP, Munger JS, Rifkin DB 2003 Making sense of latent TGFβ activation. J Cell Sci 116:217-224
24. Annes J, Vassallo M, Munger JS, Rifkin DB 2004 A genetic screen to identify latent transforming growth factor β activators. Anal Biochem 327:45-54
25. Oreffo RO, Mundy GR, Seyedin SM, Bonewald LF 1989 Activation of the bone-derived latent TGF β complex by isolated osteoclasts. Biochem Biophys Res Commun 158:817-823
26. Oursler MJ 1994 Osteoclast synthesis and secretion and activation of latent transforming growth factor β. J Bone Miner Res 9:443-452
27. Derynck R, Feng XH 1997 TGF-β receptor signaling. Biochim Biophys Acta 1333:F105-F150
28. Lopez-Casillas F, Wrana JL, Massague J 1993 Betaglycan presents ligand to the TGF β signaling receptor. Cell 73:1435-1444
29. Sankar S, Mahooti-Brooks N, Centrella M, McCarthy TL, Madri JA 1995 Expression of transforming growth factor type III receptor in vascular endothelial cells increases their responsiveness to transforming growth factor β 2. J Biol Chem 270:13567-13572
30. Stenvers KL, Tursky ML, Harder KW, Kountouri N, Amatayakul-Chantler S, Grail D, Small C, Weinberg RA, Sizeland AM, Zhu HJ 2003 Heart and liver defects and reduced transforming growth factor β2 sensitivity in transforming growth factor β type III receptor-deficient embryos. Mol Cell Biol 23:4371-4385
31. Lopez-Casillas F, Payne HM, Andres JL, Massague J 1994 Betaglycan can act as a dual modulator of TGF-β access to signaling receptors: mapping of ligand binding and GAG attachment sites. J Cell Biol 124:557-568
32. Chen W, Kirkbride KC, How T, Nelson CD, Mo J, Frederick JP, Wang XF, Lefkowitz RJ, Blobe GC 2003 β-Arrestin 2 mediates endocytosis of type III TGF-β receptor and down-regulation of its signaling. Science 301:1394-1397
33. Cheifetz S, Bellon T, Cales C, Vera S, Bernabeu C, Massague J, Letarte M 1992 Endoglin is a component of the transforming growth factor-β receptor system in human endothelial cells. J Biol Chem 267:19027-19030
34. McAllister KA, Grogg KM, Johnson DW, Gallione CJ, Baldwin MA, Jackson CE, Helmbold EA, Markel DS, McKinnon WC, Murrell J, McCormick MK, Pericak-Vance MA, Heutink P, Oostra BA, Haitjema T, Westerman CJJ, Porteous ME, Guttmacher AE, Letarte M, Marchuk DA 1994 Endoglin, a TGF-β binding protein of endothelial cells, is the gene for hereditary haemorrhagic telangiectasia type 1. Nat Genet 8:345-351
35. Bourdeau A, Dumont DJ, Letarte M 1999 A murine model of hereditary hemorrhagic telangiectasia. J Clin Invest 104:1343-1351
36. Walsh S, Jefferiss C, Stewart K, Beresford JN 2003 TGFβ1 limits the expansion of the osteoprogenitor fraction in cultures of human bone marrow stromal cells. Cell Tissue Res 311:187-198
37. Massagué J 1998 TGF-β signal transduction. Annu Rev Biochem 67:753-791
38. Sekelsky JJ, Newfeld SJ, Raftery LA, Chartoff EH, Gelbart WM 1995 Genetic characterization and cloning of mothers against dpp, a gene required for decapentaplegic function in Drosophila melanogaster. Genetics 139:1347-1358
39. Savage C, Das P, Finelli AL, Townsend SR, Sun CY, Baird SE, Padgett RW 1996 Caenorhabditis elegans genes sma-2, sma-3, and sma-4 define a conserved family of transforming growth factor β pathway components. Proc Natl Acad Sci USA 93:790-794
40. Padgett RW, Savage C, Das P 1997 Genetic and biochemical analysis of TGF β signal transduction. Cytokine Growth Factor Rev 8:1-9
41. Wrana JL, Attisano L 2000 The Smad pathway. Cytokine Growth Factor Rev 11:5-13
42. Shi Y, Massague J 2003 Mechanisms of TGF-β signaling from cell membrane to the nucleus. Cell 113:685-700
43. ten Dijke P, Hill CS 2004 New insights into TGF-β-Smad signalling. Trends Biochem Sci 29:265-273
44. Zhang F, Laiho M 2003 On and off: proteasome and TGF-β signaling. Exp Cell Res 291:275-281
45. Izzi L, Attisano L 2004 Regulation of the TGFβ signalling pathway by ubiquitin-mediated degradation. Oncogene 23:2071-2078
46. Shi W, Sun C, He B, Xiong W, Shi X, Yao D, Cao X 2004 GADD34-PP1c recruited by Smad7 dephosphorylates TGFβ type I receptor. J Cell Biol 164:291-300
47. Tsukazaki T, Chiang TA, Davison AF, Attisano L, Wrana JL 1998 SARA, a FYVE domain protein that recruits Smad2 to the TGFβ receptor. Cell 95:779-791
48. Wu G, Chen YG, Ozdamar B, Gyuricza CA, Chong PA, Wrana JL, Massague J, Shi Y 2000 Structural basis of Smad2 recognition by the Smad anchor for receptor activation. Science 287:92-97
49. Di Guglielmo GM, Le Roy C, Goodfellow AF, Wrana JL 2003 Distinct endocytic pathways regulate TGF-β receptor signalling and turnover. Nat Cell Biol 5:410-421
50. Wu JW, Fairman R, Penry J, Shi Y 2001 Formation of a stable heterodimer between Smad2 and Smad4. J Biol Chem 276:20688-20694
51. Qin BY, Lam SS, Correia JJ, Lin K 2002 Smad3 allostery links TGF-β receptor kinase activation to transcriptional control. Genes Dev 16:1950-1963
52. Inman GJ, Hill CS 2002 Stoichiometry of active smad-transcription factor complexes on DNA. J Biol Chem 277:51008-51116
53. Chacko BM, Qin BY, Tiwari A, Shi G, Lam S, Hayward LJ, De Caestecker M, Lin K 2004 Structural basis of heteromeric smad protein assembly in TGF-β signaling. Mol Cell 15:813-823
54. Miyazawa K, Shinozaki M, Hara T, Furuya T, Miyazono K 2002 Two major Smad pathways in TGF-β superfamily signalling. Genes Cells 7:1191-1204
55. Sirard C, Kim S, Mirtsos C, Tadich P, Hoodless PA, Itie A, Maxson R, Wrana JL, Mak TW 2000 Targeted disruption in murine cells reveals variable requirement for Smad4 in transforming growth factor β-related signaling. J Biol Chem 275:2063-2070
56. Dai JL, Schutte M, Bansal RK, Wilentz RE, Sugar AY, Kern SE 1999 Transforming growth factor-β responsiveness in DPC4/SMAD4-null cancer cells. Mol Carcinog 26:37-43
57. Hocevar BA, Brown TL, Howe PH 1999 TGF-β induces fibronectin synthesis through a c-Jun N-terminal kinase-dependent, Smad4-independent pathway. EMBO J 18:1345-1356
58. Yu L, Hebert MC, Zhang YE 2002 TGF-β receptor-activated p38 MAP kinase mediates Smad-independent TGF-β responses. EMBO J 21:3749-3759
59. Itoh S, Thorikay M, Kowanetz M, Moustakas A, Itoh F, Heldin CH, ten Dijke P 2003 Elucidation of Smad requirement in transforming growth factor-β type I receptor-induced responses. J Biol Chem 278:3751-3761
60. Mulder KM 2000 Role of Ras and Mapks in TGFβ signaling. Cytokine Growth Factor Rev 11:23-35
61. Johnson GL, Lapadat R 2002 Mitogen-activated protein kinase pathways mediated by ERK, JNK, and p38 protein kinases. Science 298:1911-1912
62. Yamamura Y, Hua X, Bergelson S, Lodish HF 2000 Critical role of Smads and AP-1 complex in transforming growth factor-β-dependent apoptosis. J Biol Chem 275:36295-36302
63. Sano Y, Harada J, Tashiro S, Gotoh-Mandeville R, Maekawa T, Ishii S 1999 ATF-2 is a common nuclear target of Smad and TAK1 pathways in transforming growth factor-β signaling. J Biol Chem 274:8949-8957
64. Edlund S, Landstrom M, Heldin CH, Aspenstrom P 2002 Transforming growth factor-β-induced mobilization of actin cytoskeleton requires signaling by small GTPases Cdc42 and RhoA. Mol Biol Cell 13:902-914
65. Atfi A, Djelloul S, Chastre E, Davis R, Gespach C 1997 Evidence for a role of Rho-like GTPases and stress-activated protein kinase/c-Jun N-terminal kinase (SAPK/JNK) in transforming growth factor β-mediated signaling. J Biol Chem 272:1429-1432
66. Engel ME, McDonnell MA, Law BK, Moses HL 1999 Interdependent SMAD and JNK signaling in transforming growth factor-β-mediated transcription. J Biol Chem 274:37413-37420
67. Rodriguez-Barbero A, Obreo J, Yuste L, Montero JC, Rodriguez-Pena A, Pandiella A, Bernabeu C, Lopez-Novoa JM 2002 Transforming growth factor-β1 induces collagen synthesis and accumulation via p38 mitogen-activated protein kinase (MAPK) pathway in cultured L(6)E(9) myoblasts. FEBS Lett 513:282-288
68. Rousse S, Lallemand F, Montarras D, Pinset C, Mazars A, Prunier C, Atfi A, Dubois C 2001 Transforming growth factor-β inhibition of insulin-like growth factor-binding protein-5 synthesis in skeletal muscle cells involves a c-Jun N-terminal kinase-dependent pathway. J Biol Chem 276:46961-46967
69. Chin BY, Petrache I, Choi AM, Choi ME 1999 Transforming growth factor β1 rescues serum deprivation-induced apoptosis via the mitogen-activated protein kinase (MAPK) pathway in macrophages. J Biol Chem 274:11362-11368
70. Zhou G, Lee SC, Yao Z, Tan TH 1999 Hematopoietic progenitor kinase 1 is a component of transforming growth factor β-induced c-Jun N-terminal kinase signaling cascade. J Biol Chem 274:13133-13138
71. Chung KY, Agarwal A, Uitto J, Mauviel A 1996 An AP-1 binding sequence is essential for regulation of the human α2(I) collagen (COL1A2) promoter activity by transforming growth factor-β. J Biol Chem 271:3272-3278
72. Brodin G, Ahgren A, ten Dijke P, Heldin CH, Heuchel R 2000 Efficient TGF-β induction of the Smad7 gene requires cooperation between AP-1, Sp1, and Smad proteins on the mouse Smad7 promoter. J Biol Chem 275:29023-29030
73. Banerjee C, Stein JL, Van Wijnen AJ, Frenkel B, Lian JB, Stein GS 1996 Transforming growth factor-β 1 responsiveness of the rat osteocalcin gene is mediated by an activator protein-1 binding site. Endocrinology 137:1991-2000
74. Keeton MR, Curriden SA, van Zonneveld AJ, Loskutoff DJ 1991 Identification of regulatory sequences in the type 1 plasminogen activator inhibitor gene responsive to transforming growth factor β. J Biol Chem 266:23048-23052
75. Hall MC, Young DA, Waters JG, Rowan AD, Chantry A, Edwards DR, Clark IM 2003 The comparative role of activator protein 1 and Smad factors in the regulation of Timp-1 and MMP-1 gene expression by transforming growth factor-β 1. J Biol Chem 278:10304-10313
76. Liberati NT, Datto MB, Frederick JP, Shen X, Wong C, Rougier-Chapman EM, Wang XF 1999 Smads bind directly to the Jun family of AP-1 transcription factors. Proc Natl Acad Sci USA 96:4844-4849
77. Zhang Y, Feng XH, Derynck R 1998 Smad3 and Smad4 cooperate with c-Jun/c-Fos to mediate TGF-β-induced transcription. Nature 394:909-913
78. Pessah M, Prunier C, Marais J, Ferrand N, Mazars A, Lallemand F, Gauthier JM, Atfi A 2001 c-Jun interacts with the corepressor TG-interacting factor (TGIF) to suppress Smad2 transcriptional activity. Proc Natl Acad Sci USA 98:6198-6203
79. Pessah M, Marais J, Prunier C, Ferrand N, Lallemand F, Mauviel A, Atfi A 2002 c-Jun associates with the oncoprotein Ski and suppresses Smad2 transcriptional activity. J Biol Chem 277:29094-29100
80. Yang YC, Piek E, Zavadil J, Liang D, Xie D, Heyer J, Pavlidis P, Kucherlapati R, Roberts AB, Bottinger EP 2003 Hierarchical model of gene regulation by transforming growth factor β. Proc Natl Acad Sci USA 100:10269-10274
81. Wada T, Penninger JM 2004 Mitogen-activated protein kinases in apoptosis regulation. Oncogene 23:2838-2849
82. Jochum W, Passegue E, Wagner EF 2001 AP-1 in mouse development and tumorigenesis. Oncogene 20:2401-2412
83. Wagner EF 2002 Functions of AP1 (Fos/Jun) in bone development. Ann Rheum Dis 61(Suppl 2):ii40-ii42
84. Zhang L, Wang W, Hayashi Y, Jester JV, Birk DE, Gao M, Liu CY, Kao WW, Karin M, Xia Y 2003 A role for MEK kinase 1 in TGF-β/activin-induced epithelium movement and embryonic eyelid closure. EMBO J 22:4443-4454
85. Wang L, Kwak JH, Kim SI, He Y, Choi ME 2004 Transforming growth factor-β1 stimulates vascular endothelial growth factor 164 via mitogen-activated protein kinase kinase 3-p38α and p38δ mitogen-activated protein kinase-dependent pathway in murine mesangial cells. J Biol Chem 279:33213-33219
86. Wang W, Zhou G, Hu MC, Yao Z, Tan TH 1997 Activation of the hematopoietic progenitor kinase-1 (HPK1)-dependent, stress-activated c-Jun N-terminal kinase (JNK) pathway by transforming growth factor β (TGF-β)-activated kinase (TAK1), a kinase mediator of TGF β signal transduction. J Biol Chem 272:22771-22775
87. Yamaguchi K, Nagai S, Ninomiya-Tsuji J, Nishita M, Tamai K, Irie K, Ueno N, Nishida E, Shibuya H, Matsumoto K 1999 XIAP, a cellular member of the inhibitor of apoptosis protein family, links the receptors to TAB1-TAK1 in the BMP signaling pathway. EMBO J 18:179-187
88. Birkey Reffey S, Wurthner JU, Parks WT, Roberts AB, Duckett CS 2001 X-linked inhibitor of apoptosis protein functions as a cofactor in transforming growth factor-β signaling. J Biol Chem 276:26542-26549
89. Komatsu Y, Shibuya H, Takeda N, Ninomiya-Tsuji J, Yasui T, Miyado K, Sekimoto T, Ueno N, Matsumoto K, Yamada G 2002 Targeted disruption of the Tab1 gene causes embryonic lethality and defects in cardiovascular and lung morphogenesis. Mech Dev 119:239-249
90. Pilkington MF, Sims SM, Dixon SJ 2001 Transforming growth factor-β induces osteoclast ruffling and chemotaxis: potential role in osteoclast recruitment. J Bone Miner Res 16:1237-1247
91. Karsdal MA, Hjorth P, Henriksen K, Kirkegaard T, Nielsen KL, Lou H, Delaisse JM, Foged NT 2003 Transforming growth factor-β controls human osteoclastogenesis through the p38 MAPK and regulation of RANK expression. J Biol Chem 278:44975-44987
92. Karsdal MA, Fjording MS, Foged NT, Delaisse JM, Lochter A 2001 Transforming growth factor-β-induced osteoblast elongation regulates osteoclastic bone resorption through a p38 mitogen-activated protein kinase- and matrix metalloproteinase-dependent pathway. J Biol Chem 276:39350-39358
93. Karsdal MA, Larsen L, Engsig MT, Lou H, Ferreras M, Lochter A, Delaisse JM, Foged NT 2002 Matrix metalloproteinase-dependent activation of latent transforming growth factor-β controls the conversion of osteoblasts into osteocytes by blocking osteoblast apoptosis. J Biol Chem 277:44061-44067
94. Lee KS, Hong SH, Bae SC 2002 Both the Smad and p38 MAPK pathways play a crucial role in Runx2 expression following induction by transforming growth factor-β and bone morphogenetic protein. Oncogene 21:7156-7163
95. Palcy S, Bolivar I, Goltzman D 2000 Role of activator protein 1 transcriptional activity in the regulation of gene expression by transforming growth factor β1 and bone morphogenetic protein 2 in ROS 17/2.8 osteoblast-like cells. J Bone Miner Res 15:2352-2361
96. Palcy S, Goltzman D 1999 Protein kinase signalling pathways involved in the up-regulation of the rat α1(I) collagen gene by transforming growth factor β1 and bone morphogenetic protein 2 in osteoblastic cells. Biochem J 343:21-27
97. Selvamurugan N, Kwok S, Alliston T, Reiss M, Partridge NC 2004 Transforming growth factor-β 1 regulation of collagenase-3 expression in osteoblastic cells by cross-talk between the Smad and MAPK signaling pathways and their components, Smad2 and Runx2. J Biol Chem 279:19327-19334
98. Lai CF, Cheng SL 2002 Signal transductions induced by bone morphogenetic protein-2 and transforming growth factor-β in normal human osteoblastic cells. J Biol Chem 277:15514-15522
99. Sowa H, Kaji H, Yamaguchi T, Sugimoto T, Chihara K 2002 Activations of ERK1/2 and JNK by transforming growth factor β negatively regulate Smad3-induced alkaline phosphatase activity and mineralization in mouse osteoblastic cells. J Biol Chem 277:36024-36031
100. Derynck R, Zhang YE 2003 Smad-dependent and Smad-independent pathways in TGF-β family signalling. Nature 425:577-584
101. Ducy P, Zhang R, Geoffroy V, Ridall AL, Karsenty G 1997 Osf2/Cbfa1: a transcriptional activator of osteoblast differentiation. Cell 89:747-754
102. Nakashima K, Zhou X, Kunkel G, Zhang Z, Deng JM, Behringer RR, de Crombrugghe B 2002 The novel zinc finger-containing transcription factor osterix is required for osteoblast differentiation and bone formation. Cell 108:17-29
103. Karsenty G, Wagner EF 2002 Reaching a genetic and molecular understanding of skeletal development. Dev Cell 2:389-406
104. Ducy P, Schinke T, Karsenty G 2000 The osteoblast: a sophisticated fibroblast under central surveillance. Science 289:1501-1504
105. Harada S, Rodan GA 2003 Control of osteoblast function and regulation of bone mass. Nature 423:349-355
106. Teitelbaum SL, Ross FP 2003 Genetic regulation of osteoclast development and function. Nat Rev Genet 4:638-649
107. Luchin A, Purdom G, Murphy K, Clark MY, Angel N, Cassady AI, Hume DA, Ostrowski MC 2000 The microphthalmia transcription factor regulates expression of the tartrate-resistant acid phosphatase gene during terminal differentiation of osteoclasts. J Bone Miner Res 15:451-460
108. Luchin A, Suchting S, Merson T, Rosol TJ, Hume DA, Cassady AI, Ostrowski MC 2001 Genetic and physical interactions between Microphthalmia transcription factor and PU. 1 are necessary for osteoclast gene expression and differentiation. J Biol Chem 276:36703-36710
109. Takayanagi H, Kim S, Koga T, Nishina H, Isshiki M, Yoshida H, Saiura A, Isobe M, Yokochi T, Inoue J, Wagner EF, Mak TW, Kodama T, Taniguchi T 2002 Induction and activation of the transcription factor NFATc1 (NFAT2) integrate RANKL signaling in terminal differentiation of osteoclasts. Dev Cell 3:889-901
110. Kaifu T, Nakahara J, Inui M, Mishima K, Momiyama T, Kaji M, Sugahara A, Koito H, Ujike-Asai A, Nakamura A, Kanazawa K, Tan-Takeuchi K, Iwasaki K, Yokoyama WM, Kudo A, Fujiwara M, Asou H, Takai T 2003 Osteopetrosis and thalamic hypomyelinosis with synaptic degeneration in DAP12-deficient mice. J Clin Invest 111:323-332
111. Wagner EF, Karsenty G 2001 Genetic control of skeletal development. Curr Opin Genet Dev 11:527-532
112. Boyle WJ, Simonet WS, Lacey DL 2003 Osteoclast differentiation and activation. Nature 423:337-342
113. Hering S, Isken E, Knabbe C, Janott J, Jost C, Pommer A, Muhr G, Schatz H, Pfeiffer AF 2001 TGFβ1 and TGFβ2 mRNA and protein expression in human bone samples. Exp Clin Endocrinol Diabetes 109:217-226
114. Pelton RW, Saxena B, Jones M, Moses HL, Gold LI 1991 Immunohistochemical localization of TGFβ1, TGF β2, and TGFβ3 in the mouse embryo: expression patterns suggest multiple roles during embryonic development. J Cell Biol 115:1091-1105
115. Thompson NL, Flanders KC, Smith JM, Ellingsworth LR, Roberts AB, Sporn MB 1989 Expression of transforming growth factor-β 1 in specific cells and tissues of adult and neonatal mice. J Cell Biol 108:661-669
116. Horner A, Kemp P, Summers C, Bord S, Bishop NJ, Kelsall AW, Coleman N, Compston JE 1998 Expression and distribution of transforming growth factor-β isoforms and their signaling receptors in growing human bone. Bone 23:95-102
117. Sandberg M, Vuorio T, Hirvonen H, Alitalo K, Vuorio E 1988 Enhanced expression of TGF-β and c-fos mRNAs in the growth plates of developing human long bones. Development 102:461-470
118. Cho TJ, Gerstenfeld LC, Einhorn TA 2002 Differential temporal expression of members of the transforming growth factor β superfamily during murine fracture healing. J Bone Miner Res 17:513-520
119. Bonewald LF, Wakefield L, Oreffo RO, Escobedo A, Twardzik DR, Mundy GR 1991 Latent forms of transforming growth factor-β (TGF β) derived from bone cultures: identification of a naturally occurring 100-kDa complex with similarity to recombinant latent TGF β. Mol Endocrinol 5:741-751
120. Pedrozo HA, Schwartz Z, Robinson M, Gomes R, Dean DD, Bonewald LF, Boyan BD 1999 Potential mechanisms for the plasmin-mediated release and activation of latent transforming growth factor-β1 from the extracellular matrix of growth plate chondrocytes. Endocrinology 140:5806-5816
121. Olofsson A, Miyazono K, Kanzaki T, Colosetti P, Engstrom U, Heldin CH 1992 Transforming growth factor-β1, -β2, and -β3 secreted by a human glioblastoma cell line. Identification of small and different forms of large latent complexes. J Biol Chem 267:19482-19488
122. Wakefield LM, Letterio JJ, Chen T, Danielpour D, Allison RS, Pai LH, Denicoff AM, Noone MH, Cowan KH, O'Shaughnessy JA, Sporn MB 1995 Transforming growth factor-β1 circulates in normal human plasma and is unchanged in advanced metastatic breast cancer. Clin Cancer Res 1:129-136
123. Alliston T, Choy L, Ducy P, Karsenty G, Derynck R 2001 TGF-β-induced repression of CBFA1 by Smad3 decreases cbfa1 and osteocalcin expression and inhibits osteoblast differentiation. EMBO J 20:2254-2272
124. Maeda S, Hayashi M, Komiya S, Imamura T, Miyazono K 2004 Endogenous TGF-β signaling suppresses maturation of osteoblastic mesenchymal cells. EMBO J 23:552-563
125. Canalis E, Economides AN, Gazzerro E 2003 Bone morphogenetic proteins, their antagonists, and the skeleton. Endocr Rev 24:218-235
126. Karsdal MA, Andersen TA, Bonewald L, Christiansen C 2004 Matrix metalloproteinases (MMPs) safeguard osteoblasts from apoptosis during transdifferentiation into osteocytes: MT1-MMP maintains osteocyte viability. DNA Cell Biol 23:155-165
127. Jilka RL, Weinstein RS, Bellido T, Parfitt AM, Manolagas SC 1998 Osteoblast programmed cell death (apoptosis): modulation by growth factors and cytokines. J Bone Miner Res 13:793-802
128. Katagiri T, Yamaguchi A, Komaki M, Abe E, Takahashi N, Ikeda T, Rosen V, Wozney JM, Fujisawa-Sehara A, Suda T 1994 Bone morphogenetic protein-2 converts the differentiation pathway of C2C12 myoblasts into the osteoblast lineage. J Cell Biol 127:1755-1766
129. Lucas PA 1989 Chemotactic response of osteoblast-like cells to transforming growth factor β. Bone 10:459-463
130. Pfeilschifter J, Wolf O, Naumann A, Minne HW, Mundy GR, Ziegler R 1990 Chemotactic response of osteoblastlike cells to transforming growth factor β. J Bone Miner Res 5:825-830
131. Hughes FJ, Aubin JE, Heersche JN 1992 Differential chemotactic responses of different populations of fetal rat calvaria cells to platelet-derived growth factor and transforming growth factor β. Bone Miner 19:63-74
132. Centrella M, Massague J, Canalis E 1986 Human platelet-derived transforming growth factor-β stimulates parameters of bone growth in fetal rat calvariae. Endocrinology 119:2306-2312
133. Robey PG, Young MF, Flanders KC, Roche NS, Kondaiah P, Reddi AH, Termine JD, Sporn MB, Roberts AB 1987 Osteoblasts synthesize and respond to transforming growth factor-type β (TGF-β) in vitro. J Cell Biol 105:457-463
134. Hock JM, Canalis E, Centrella M 1990 Transforming growth factor-β stimulates bone matrix apposition and bone cell replication in cultured fetal rat calvariae. Endocrinology 126:421-426
135. Chen TL, Bates RL 1993 Recombinant human transforming growth factor β 1 modulates bone remodeling in a mineralizing bone organ culture. J Bone Miner Res 8:423-434
136. Yamada T, Kamiya N, Harada D, Takagi M 1999 Effects of transforming growth factor-β1 on the gene expression of decorin, biglycan, and alkaline phosphatase in osteoblast precursor cells and more differentiated osteoblast cells. Histochem J 31:687-694
137. Kassem M, Kveiborg M, Eriksen EF 2000 Production and action of transforming growth factor-β in human osteoblast cultures: dependence on cell differentiation and modulation by calcitriol. Eur J Clin Invest 30:429-437
138. Noda M, Rodan GA 1987 Type β transforming growth factor (TGF β) regulation of alkaline phosphatase expression and other phenotype-related mRNAs in osteoblastic rat osteosarcoma cells. J Cell Physiol 133:426-437
139. Antosz ME, Bellows CG, Aubin JE 1989 Effects of transforming growth factor β and epidermal growth factor on cell proliferation and the formation of bone nodules in isolated fetal rat calvaria cells. J Cell Physiol 140:386-395
140. Centrella M, McCarthy TL, Canalis E 1987 Transforming growth factor β is a bifunctional regulator of replication and collagen synthesis in osteoblast-enriched cell cultures from fetal rat bone. J Biol Chem 262:2869-2874
141. Wrana JL, Maeno M, Hawrylyshyn B, Yao KL, Domenicucci C, Sodek J 1988 Differential effects of transforming growth factor-β on the synthesis of extracellular matrix proteins by normal fetal rat calvarial bone cell populations. J Cell Biol 106:915-924
142. Harris SE, Bonewald LF, Harris MA, Sabatini M, Dallas S, Feng JQ, Ghosh-Choudhury N, Wozney J, Mundy GR 1994 Effects of transforming growth factor β on bone nodule formation and expression of bone morphogenetic protein 2, osteocalcin, osteopontin, alkaline phosphatase, and type I collagen mRNA in long-term cultures of fetal rat calvarial osteoblasts. J Bone Miner Res 9:855-863
143. Breen EC, Ignotz RA, McCabe L, Stein JL, Stein GS, Lian JB 1994 TGF β alters growth and differentiation related gene expression in proliferating osteoblasts in vitro, preventing development of the mature bone phenotype. J Cell Physiol 160:323-335
144. Noda M, Yoon K, Prince CW, Butler WT, Rodan GA 1988 Transcriptional regulation of osteopontin production in rat osteosarcoma cells by type β transforming growth factor. J Biol Chem 263:13916-13921
145. Rosen DM, Stempien SA, Thompson AY, Seyedin SM 1988 Transforming growth factor-β modulates the expression of osteoblast and chondroblast phenotypes in vitro. J Cell Physiol 134:337-346
146. Noda M 1989 Transcriptional regulation of osteocalcin production by transforming growth factor-β in rat osteoblast-like cells. Endocrinology 124:612-617
147. Harris SE, Sabatini M, Harris MA, Feng JQ, Wozney J, Mundy GR 1994 Expression of bone morphogenetic protein messenger RNA in prolonged cultures of fetal rat calvarial cells. J Bone Miner Res 9:389-394
148. Sowa H, Kaji H, Yamaguchi T, Sugimoto T, Chihara K 2002 Smad3 promotes alkaline phosphatase activity and mineralization of osteoblastic MC3T3-E1 cells. J Bone Miner Res 17:1190-1199
149. Stein GS, Lian JB, van Wijnen AJ, Stein JL, Montecino M, Javed A, Zaidi SK, Young DW, Choi JY, Pockwinse SM 2004 Runx2 control of organization, assembly and activity of the regulatory machinery for skeletal gene expression. Oncogene 23:4315-4329
150. Lee MH, Javed A, Kim HJ, Shin HI, Gutierrez S, Choi JY, Rosen V, Stein JL, van Wijnen AJ, Stein GS, Lian JB, Ryoo HM 1999 Transient upregulation of CBFA1 in response to bone morphogenetic protein-2 and transforming growth factor β1 in C2C12 myogenic cells coincides with suppression of the myogenic phenotype but is not sufficient for osteoblast differentiation. J Cell Biochem 73:114-125
151. Lee KS, Kim HJ, Li QL, Chi XZ, Ueta C, Komori T, Wozney JM, Kim EG, Choi JY, Ryoo HM, Bae SC 2000 Runx2 is a common target of transforming growth factor β1 and bone morphogenetic protein 2, and cooperation between Runx2 and Smad5 induces osteoblast-specific gene expression in the pluripotent mesenchymal precursor cell line C2C12. Mol Cell Biol 20:8783-8792
152. Spinella-Jaegle S, Roman-Roman S, Faucheu C, Dunn FW, Kawai S, Gallea S, Stiot V, Blanchet AM, Courtois B, Baron R, Rawadi G 2001 Opposite effects of bone morphogenetic protein-2 and transforming growth factor-β1 on osteoblast differentiation. Bone 29:323-330
153. Li J, Tsuji K, Komori T, Miyazono K, Wrana JL, Ito Y, Nifuji A, Noda M 1998 Smad2 overexpression enhances Smad4 gene expression and suppresses CBFA1 gene expression in osteoblastic osteosarcoma ROS17/2.8 cells and primary rat calvaria cells. J Biol Chem 273:31009-31015
154. Sowa H, Kaji H, Hendy GN, Canaff L, Komori T, Sugimoto T, Chihara K 2004 Menin is required for BMP-2-and TGF-β-regulated osteoblastic differentiation through interaction with Smads and Runx2. J Biol Chem 279:40267-40275
155. Centrella M, Casinghino S, Kim J, Pham T, Rosen V, Wozney J, McCarthy TL 1995 Independent changes in type I and type II receptors for transforming growth factor β induced by bone morphogenetic protein 2 parallel expression of the osteoblast phenotype. Mol Cell Biol 15:3273-3281
156. Takeuchi Y, Nakayama K, Matsumoto T 1996 Differentiation and cell surface expression of transforming growth factor-β receptors are regulated by interaction with matrix collagen in murine osteoblastic cells. J Biol Chem 271:3938-3944
157. Centrella M, Ji C, Casinghino S, McCarthy TL 1996 Rapid flux in transforming growth factor-β receptors on bone cells. J Biol Chem 271:18616-18622
158. Gebken J, Feydt A, Brinckmann J, Notbohm H, Muller PK, Batge B 1999 Ligand-induced downregulation of receptors for TGF-β in human osteoblast-like cells from adult donors. J Endocrinol 161:503-510
159. Chénu C, Pfeilschifter J, Mundy GR, Roodman GD 1988 Transforming growth factor β inhibits formation of osteoclast-like cells in long-term human marrow cultures. Proc Natl Acad Sci USA 85:5683-5687
160. Shinar DM, Rodan GA 1990 Biphasic effects of transforming growth factor-β on the production of osteoclast-like cells in mouse bone marrow cultures: the role of prostaglandins in the generation of these cells. Endocrinology 126:3153-3158
161. Yamaguchi M, Kishi S 1995 Differential effects of transforming growth factor-β on osteoclast-like cell formation in mouse marrow culture: relation to the effect of zinc-chelating dipeptides. Peptides 16:1483-1488
162. Hattersley G, Chambers TJ 1991 Effects of transforming growth factor β 1 on the regulation of osteoclastic development and function. J Bone Miner Res 6:165-172
163. Kale VP 2004 Differential activation of MAPK signaling pathways by TGF-β1 forms the molecular mechanism behind its dose-dependent bidirectional effects on hematopoiesis. Stem Cells Dev 13:27-38
164. Kale VP, Vaidya AA 2004 Molecular mechanisms behind the dose-dependent differential activation of MAPK pathways induced by transforming growth factor-β1 in hematopoietic cells. Stem Cells Dev 13:536-547
165. Takai H, Kanematsu M, Yano K, Tsuda E, Higashio K, Ikeda K, Watanabe K, Yamada Y 1998 Transforming growth factor-β stimulates the production of osteoprotegerin/osteoclastogenesis inhibitory factor by bone marrow stromal cells. J Biol Chem 273:27091-27096
166. Karst M, Gorny G, Galvin RJ, Oursler MJ 2004 Roles of stromal cell RANKL, OPG, and M-CSF expression in biphasic TGF-β regulation of osteoclast differentiation. J Cell Physiol 200:99-106
167. Dieudonné SC, Foo P, van Zoelen EJ, Burger EH 1991 Inhibiting and stimulating effects of TGF-β 1 on osteoclastic bone resorption in fetal mouse bone organ cultures. J Bone Miner Res 6:479-487
168. Massey HM, Scopes J, Horton MA, Flanagan AM 2001 Transforming growth factor-β1 (TGF-β) stimulates the osteoclast-forming potential of peripheral blood hematopoietic precursors in a lymphocyte-rich microenvironment. Bone 28:577-582
169. Kaneda T, Nojima T, Nakagawa M, Ogasawara A, Kaneko H, Sato T, Mano H, Kumegawa M, Hakeda Y 2000 Endogenous production of TGF-β is essential for osteoclastogenesis induced by a combination of receptor activator of NF-κ B ligand and macrophagecolony-stimulating factor. J Immunol 165:4254-4263
170. Koseki T, Gao Y, Okahashi N, Murase Y, Tsujisawa T, Sato T, Yamato K, Nishihara T 2002 Role of TGF-β family in osteoclastogenesis induced by RANKL. Cell Signal 14:31-36
171. Chin SL, Johnson SA, Quinn J, Mirosavljevic D, Price JT, Dudley AC, Thomas DM 2003 A role for αV integrin subunit in TGF-β-stimulated osteoclastogenesis. Biochem Biophys Res Commun 307:1051-1058
172. Fuller K, Lean JM, Bayley KE, Wani MR, Chambers TJ 2000 A role for TGFβ(1) in osteoclast differentiation and survival. J Cell Sci 113:2445-2453
173. Sells Galvin RJ, Gatlin CL, Horn JW, Fuson TR 1999 TGF-β enhances osteoclast differentiation in hematopoietic cell cultures stimulated with RANKL and M-CSF. Biochem Biophys Res Commun 265:233-239
174. Yan T, Riggs BL, Boyle WJ, Khosla S 2001 Regulation of osteoclastogenesis and RANK expression by TGF-β1. J Cell Biochem 83:320-325
175. Fox SW, Haque SJ, Lovibond AC, Chambers TJ 2003 The possible role of TGF-β-induced suppressors of cytokine signaling expression in osteoclast/macrophage lineage commitment in vitro. J Immunol 170:3679-3687
176. Tashjian Jr AH, Voelkel EF, Lazzaro M, Singer FR, Roberts AB, Derynck R, Winkler ME, Levine L 1985 α And β human transforming growth factors stimulate prostaglandin production and bone resorption in cultured mouse calvaria. Proc Natl Acad Sci USA 82:4535-4538
177. Pfeilschifter J, Seyedin SM, Mundy GR 1988 Transforming growth factor β inhibits bone resorption in fetal rat long bone cultures. J Clin Invest 82:680-685
178. Lerner UH 1996 Transforming growth factor-β stimulates bone resorption in neonatal mouse calvariae by a prostaglandin-unrelated but cell proliferation-dependent pathway. J Bone Miner Res 11:1628-1639
179. Baltzer AW, Lattermann C, Whalen JD, Wooley P, Weiss K, Grimm M, Ghivizzani SC, Robbins PD, Evans CH 2000 Genetic enhancement of fracture repair: healing of an experimental segmental defect by adenoviral transfer of the BMP-2 gene. Gene Ther 7:734-739
180. Park J, Ries J, Gelse K, Kloss F, von der Mark K, Wiltfang J, Neukam FW, Schneider H 2003 Bone regeneration in critical size defects by cell-mediated BMP-2 gene transfer: a comparison of adenoviral vectors and liposomes. Gene Ther 10:1089-1098
181. Khan SN, Lane JM 2004 The use of recombinant human bone morphogenetic protein-2 (rhBMP-2) in orthopaedic applications. Expert Opin Biol Ther 4:741-748
182. Kanatani M, Sugimoto T, Kaji H, Kobayashi T, Nishiyama K, Fukase M, Kumegawa M, Chihara K 1995 Stimulatory effect of bone morphogenetic protein-2 on osteoclast-like cell formation and bone-resorbing activity. J Bone Miner Res 10:1681-1690
183. Itoh K, Udagawa N, Katagiri T, Iemura S, Ueno N, Yasuda H, Higashio K, Quinn JM, Gillespie MT, Martin TJ, Suda T, Takahashi N 2001 Bone morphogenetic protein 2 stimulates osteoclast differentiation and survival supported by receptor activator of nuclear factor-κB ligand. Endocrinology 142:3656-3662
184. Zheng MH, Wood DJ, Wysocki S, Papadimitriou JM, Wang EA 1994 Recombinant human bone morphogenetic protein-2 enhances expression of interleukin-6 and transforming growth factor-β 1 genes in normal human osteoblast-like cells. J Cell Physiol 159:76-82
185. Si X, Jin Y, Yang L, Tipoe GL, White FH 1997 Expression of BMP-2 and TGF-β 1 mRNA during healing of the rabbit mandible. Eur J Oral Sci 105:325-330
186. Lee MH, Kim YJ, Kim HJ, Park HD, Kang AR, Kyung HM, Sung JH, Wozney JM, Ryoo HM 2003 BMP-2-induced Runx2 expression is mediated by Dlx5, and TGF-β 1 opposes the BMP-2-induced osteoblast differentiation by suppression of Dlx5 expression. J Biol Chem 278:34387-34394
187. Hanada K, Solchaga LA, Caplan AI, Hering TM, Goldberg VM, Yoo JU, Johnstone B 2001 BMP-2 induction and TGF-β 1 modulation of rat periosteal cell chondrogenesis. J Cell Biochem 81:284-294
188. Hayden JM, Mohan S, Baylink DJ 1995 The insulin-like growth factor system and the coupling of formation to resorption. Bone 17(Suppl 2):93S-98S
189. Conover CA 2000 In vitro studies of insulin-like growth factor I and bone. Growth Horm IGF Res 10(Suppl B):S107-S110
190. Kveiborg M, Flyvbjerg A, Eriksen EF, Kassem M 2001 Transforming growth factor-β1 stimulates the production of insulin-like growth factor-I and insulin-like growth factor-binding protein-3 in human bone marrow stromal osteoblast progenitors. J Endocrinol 169:549-561
191. Elford PR, Lamberts SW 1990 Contrasting modulation by transforming growth factor-β-1 of insulin-like growth factor-I production in osteoblasts and chondrocytes. Endocrinology 127:1635-1639
192. Canalis E, Pash J, Gabbitas B, Rydziel S, Varghese S 1993 Growth factors regulate the synthesis of insulin-like growth factor-I in bone cell cultures. Endocrinology 133:33-38
193. Giannobile WV, Whitson SW, Lynch SE 1997 Non-coordinate control of bone formation displayed by growth factor combinations with IGF-I. J Dent Res 76:1569-1578
194. Fukumoto T, Sperling JW, Sanyal A, Fitzsimmons JS, Reinholz GG, Conover CA, O'Driscoll SW 2003 Combined effects of insulinlike growth factor-1 and transforming growth factor-β1 on periosteal mesenchymal cells during chondrogenesis in vitro. Osteoarthritis Cartilage 11:55-64
195. Schmidmaier G, Wildemann B, Gabelein T, Heeger J, Kandziora F, Haas NP, Raschke M 2003 Synergistic effect of IGF-I and TGF-β1 on fracture healing in rats: single versus combined application of IGF-I and TGF-β1. Acta Orthop Scand 74:604-610
196. Canalis E, Centrella M, McCarthy T 1988 Effects of basic fibroblast growth factor on bone formation in vitro. J Clin Invest 81:1572-1577
197. Nakamura T, Hara Y, Tagawa M, Tamura M, Yuge T, Fukuda H, Nigi H 1998 Recombinant human basic fibroblast growth factor accelerates fracture healing by enhancing callus remodeling in experimental dog tibial fracture. J Bone Miner Res 13:942-949
198. Hurley MM, Lee SK, Raisz LG, Bernecker P, Lorenzo J 1998 Basic fibroblast growth factor induces osteoclast formation in murine bone marrow cultures. Bone 22:309-316
199. Jimi E, Shuto T, Ikebe T, Jingushi S, Hirata M, Koga T 1996 Basic fibroblast growth factor inhibits osteoclast-like cell formation. J Cell Physiol 168:395-402
200. Zuo J, Jiang J, Dolce C, Holliday LS 2004 Effects of basic fibroblast growth factor on osteoclasts and osteoclast-like cells. Biochem Biophys Res Commun 318:162-167
201. Chikazu D, Hakeda Y, Ogata N, Nemoto K, Itabashi A, Takato T, Kumegawa M, Nakamura K, Kawaguchi H 2000 Fibroblast growth factor (FGF)-2 directly stimulates mature osteoclast function through activation of FGF receptor 1 and p42/p44 MAP kinase. J Biol Chem 275:31444-31450
202. Hurley MM, Abreu C, Gronowicz G, Kawaguchi H, Lorenzo J 1994 Expression and regulation of basic fibroblast growth factor mRNA levels in mouse osteoblastic MC3T3-E1 cells. J Biol Chem 269:9392-9396
203. Sobue T, Gravely T, Hand A, Min YK, Pilbeam C, Raisz LG, Zhang X, Larocca D, Florkiewicz R, Hurley MM 2002 Regulation of fibroblast growth factor 2 and fibroblast growth factor receptors by transforming growth factor β in human osteoblastic MG-63 cells. J Bone Miner Res 17:502-512
204. Globus RK, Patterson-Buckendahl P, Gospodarowicz D 1988 Regulation of bovine bone cell proliferation by fibroblast growth factor and transforming growth factor β. Endocrinology 123:98-105
205. Hock JM, Canalis E 1994 Platelet-derived growth factor enhances bone cell replication, but not differentiated function of osteoblasts. Endocrinology 134:1423-1428
206. Mitlak BH, Finkelman RD, Hill EL, Li J, Martin B, Smith T, D'Andrea M, Antoniades HN, Lynch SE 1996 The effect of systemically administered PDGF-BB on the rodent skeleton. J Bone Miner Res 11:238-247
207. Nash TJ, Howlett CR, Martin C, Steele J, Johnson KA, Hicklin DJ 1994 Effect of platelet-derived growth factor on tibial osteotomies in rabbits. Bone 15:203-208
208. Zhang Z, Chen J, Jin D 1998 Platelet-derived growth factor (PDGF)-BB stimulates osteoclastic bone resorption directly: the role of receptor β. Biochem Biophys Res Commun 251:190-194
209. Yeh YL, Kang YM, Chaibi MS, Xie JF, Graves DT 1993 IL-1 and transforming growth factor-β inhibit platelet-derived growth factor-AA binding to osteoblastic cells by reducing platelet-derived growth factor-α receptor expression. J Immunol 150:5625-5632
210. Kells AF, Coats SR, Schwartz HS, Hoover RL 1995 TGF-β and PDGF act synergistically in affecting the growth of human osteoblast-enriched cultures. Connect Tissue Res 31:117-124
211. Rydziel S, Canalis E 1996 Expression and growth factor regulation of platelet-derived growth factor B transcripts in primary osteoblast cell cultures. Endocrinology 137:4115-4119
212. Gyda M, Corisdeo S, Zaidi M, Troen BR 2001 Macrophage colony-stimulating factor suppresses osteoblast formation. Biochem Biophys Res Commun 285:328-334
213. Teitelbaum SL 2000 Bone resorption by osteoclasts. Science 289:1504-1508
214. Owens J, Chambers TJ 1993 Macrophage colony-stimulating factor (M-CSF) induces migration in osteoclasts in vitro. Biochem Biophys Res Commun 195:1401-1407
215. Takaishi T, Matsui T, Tsukamoto T, Ito M, Taniguchi T, Fukase M, Chihara K 1994 TGF-β-induced macrophage colony-stimulating factor gene expression in various mesenchymal cell lines. Am J Physiol 267:C25-C31
216. Itonaga I, Sabokbar A, Sun SG, Kudo O, Danks L, Ferguson D, Fujikawa Y, Athanasou NA 2004 Transforming growth factor-β induces osteoclast formation in the absence of RANKL. Bone 34:57-64
217. Ikeda E, Kusaka M, Hakeda Y, Yokota K, Kumegawa M, Yamamoto S 1988 Effect of interleukin 1 β on osteoblastic clone MC3T3-E1 cells. Calcif Tissue Int 43:162-166
218. Hanazawa S, Ohmori Y, Amano S, Hirose K, Miyoshi T, Kumegawa M, Kitano S 1986 Human purified interleukin-1 inhibits DNA synthesis and cell growth of osteoblastic cell line (MC3T3-E1), but enhances alkaline phosphatase activity in the cells. FEBS Lett 203:279-284
219. Rifa L 1999 Bone and cytokines: beyond IL-1, IL-6 and TNF-α. Calcif Tissue Int 64:1-7
220. Kwan Tat S, Padrines M, Theoleyre S, Heymann D, Fortun Y 2004 IL-6, RANKL, TNF-α/IL-1: interrelations in bone resorption pathophysiology. Cytokine Growth Factor Rev 15:49-60
221. Pfeilschifter J, Mundy GR 1987 Modulation of type β transforming growth factor activity in bone cultures by osteotropic hormones. Proc Natl Acad Sci USA 84:2024-2028
222. Tsai JA, Rong H, Torring O, Matsushita H, Bucht E 2000 Interleukin-1β upregulates PTHrP-mRNA expression and protein production and decreases TGF-β in normal human osteoblast-like cells. Calcif Tissue Int 66:363-369
223. Dubois CM, Ruscetti FW, Palaszynski EW, Falk LA, Oppenheim JJ, Keller JR 1990 Transforming growth factor β is a potent inhibitor of interleukin 1 (IL-1) receptor expression: proposed mechanism of inhibition of IL-1 action. J Exp Med 172:737-744
224. Park YG, Kang SK, Kim WJ, Lee YC, Kim CH 2004 Effects of TGF-β, TNF-α, IL-β and IL-6 alone or in combination, and tyrosine kinase inhibitor on cyclooxygenase expression, prostaglandin E2 production and bone resorption in mouse calvarial bone cells. Int J Biochem Cell Biol 36:2270-2280
225. Jacobsen FW, Stokke T, Jacobsen SE 1995 Transforming growth factor-β potently inhibits the viability-promoting activity of stem cell factor and other cytokines and induces apoptosis of primitive murine hematopoietic progenitor cells. Blood 86:2957-2966
226. Hughes FJ, Howells GL 1993 Interleukin-6 inhibits bone formation in vitro. Bone Miner 21:21-28
227. Taguchi Y, Yamamoto M, Yamate T, Lin SC, Mocharla H, DeTogni P, Nakayama N, Boyce BF, Abe E, Manolagas SC 1998 Interleukin-6-type cytokines stimulate mesenchymal progenitor differentiation toward the osteoblastic lineage. Proc Assoc Am Physicians 110:559-574
228. Franchimont N, Rydziel S, Canalis E 2000 Transforming growth factor-β increases interleukin-6 transcripts in osteoblasts. Bone 26:249-253
229. Gimble JM, Hudson J, Henthorn J, Hua XX, Burstein SA 1991 Regulation of interleukin 6 expression in murine bone marrow stromal cells. Exp Hematol 19:1055-1060
230. Hierl T, Borcsok I, Sommer U, Ziegler R, Kasperk C 1998 Regulation of interleukin-6 expression in human osteoblastic cells in vitro. Exp Clin Endocrinol Diabetes 106:324-333
231. Hughes FJ, Howells GL 1993 Interleukin-11 inhibits bone formation in vitro. Calcif Tissue Int 53:362-364
232. Takeuchi Y, Watanabe S, Ishii G, Takeda S, Nakayama K, Fukumoto S, Kaneta Y, Inoue D, Matsumoto T, Harigaya K, Fujita T 2002 Interleukin-11 as a stimulatory factor for bone formation prevents bone loss with advancing age in mice. J Biol Chem 277:49011-49018
233. Girasole G, Passeri G, Jilka RL, Manolagas SC 1994 Interleukin-11: a new cytokine critical for osteoclast development. J Clin Invest 93:1516-1524
234. Morinaga Y, Fujita N, Ohishi K, Tsuruo T 1997 Stimulation of interleukin-11 production from osteoblast-like cells by transforming growth factor-β and tumor cell factors. Int J Cancer 71:422-428
235. Canalis E 1987 Effects of tumor necrosis factor on bone formation in vitro. Endocrinology 121:1596-1604
236. Hill PA, Tumber A, Meikle MC 1997 Multiple extracellular signals promote osteoblast survival and apoptosis. Endocrinology 138:3849-3858
237. Kobayashi K, Takahashi N, Jimi E, Udagawa N, Takami M, Kotake S, Nakagawa N, Kinosaki M, Yamaguchi K, Shima N, Yasuda H, Morinaga T, Higashio K, Martin TJ, Suda T 2000 Tumor necrosis factor α stimulates osteoclast differentiation by a mecha-nism independent of the ODF/RANKL-RANK interaction. J Exp Med 191:275-286
238. Fox SW, Fuller K, Bayley KE, Lean JM, Chambers TJ 2000 TGF-β 1 and IFN-γ direct macrophage activation by TNF-α to osteoclastic or cytocidal phenotype. J Immunol 165:4957-4963
239. Chua CC, Chua BH, Chen Z, Landy C, Hamdy RC 2002 TGF-β1 inhibits multiple caspases induced by TNF-α in murine osteoblastic MC3T3-E1 cells. Biochim Biophys Acta 1593:1-8
240. Snoeck HW, Weekx S, Moulijn A, Lardon F, Lenjou M, Nys G, Van Ranst PC, Van Bockstaele DR, Berneman ZN 1996 Tumor necrosis factor α is a potent synergistic factor for the proliferation of primitive human hematopoietic progenitor cells and induces resistance to transforming growth factor β but not to interferon γ. J Exp Med 183:705-710
241. Verrecchia F, Tacheau C, Wagner EF, Mauviel A 2003 A central role for the JNK pathway in mediating the antagonistic activity of pro-inflammatory cytokines against transforming growth factor-β-driven SMAD3/4-specific gene expression. J Biol Chem 278:1585-1593
242. Mann GN, Jacobs TW, Buchinsky FJ, Armstrong EC, Li M, Ke HZ, Ma YF, Jee WS, Epstein S 1994 Interferon-γ causes loss of bone volume in vivo and fails to ameliorate cyclosporin A-induced osteopenia. Endocrinology 135:1077-1083
243. Smith DD, Gowen M, Mundy GR 1987 Effects of interferon-γ and other cytokines on collagen synthesis in fetal rat bone cultures. Endocrinology 120:2494-2499
244. Takahashi N, Mundy GR, Roodman GD 1986 Recombinant human interferon-γ inhibits formation of human osteoclast-like cells. J Immunol 137:3544-3549
245. Vignery A, Niven-Fairchild T, Shepard MH 1990 Recombinant murine interferon-γ inhibits the fusion of mouse alveolar macrophages in vitro but stimulates the formation of osteoclastlike cells on implanted syngeneic bone particles in mice in vivo. J Bone Miner Res 5:637-644
246. Heberden C, Denis I, Pointillart A, Mercier T 1998 TGF-β and calcitriol. Gen Pharmacol 30:145-151
247. 3. Crit Rev Eukaryot Gene Expr 11:299-317
248. van Leeuwen JP, van Driel M, van den Bemd GJ, Pols HA 2001 Vitamin D control of osteoblast function and bone extracellular matrix mineralization. Crit Rev Eukaryot Gene Expr 11:199-226
249. van Driel M, Pols HA, van Leeuwen JP 2004 Osteoblast differentiation and control by vitamin D and vitamin D metabolites. Curr Pharm Des 10:2535-2555
250. Suda T, Ueno Y, Fujii K, Shinki T 2003 Vitamin D and bone. J Cell Biochem 88:259-266
251. Finkelman RD, Linkhart TA, Mohan S, Lau KH, Baylink DJ, Bell NH 1991 Vitamin D deficiency causes a selective reduction in deposition of transforming growth factor in rat bone: possible mechanism for impaired osteoinduction. Proc Natl Acad Sci USA 88:3657-3660
252. 3 increases TGFβ1 binding to human osteoblasts. Biochem Biophys Res Commun 290:1558-1563
253. 3 action in osteoblast-like cells. Bone Miner 26:27-42
254. 3 and transforming growth factor-β signaling requires binding of VDR and Smad3 proteins to their cognate DNA recognition elements. J Biol Chem 276:15741-15746
255. 3 enhancement of osteocalcin and osteopontin transcription: reduced interactions of vitamin D receptor/retinoid X receptor complexes with vitamin E response elements. Endocrinology 137:2001-2011
256. Owen TA, Bortell R, Yocum SA, Smock SL, Zhang M, Abate C, Shalhoub V, Aronin N, Wright KL, van Wijnen AJ, Stein JL, Curran T, Lian JB, Stein GS 1990 Coordinate occupancy of AP-1 sites in the vitamin D-responsive and CCAAT box elements by Fos-Jun in the osteocalcin gene: model for phenotype suppression of transcription. Proc Natl Acad Sci USA 87:9990-9994
257. 3 and TGF-β1 on the production of insulin-like growth factor binding protein 3 in human bone marrow stromal cell cultures. APMIS 110:410-414
258. 3-induced bone resorption in mouse calvarial bone cells. Immunol Invest 32:171-186
259. Qu Q, Perala-Heape M, Kapanen A, Dahllund J, Salo J, Vaananen HK, Harkonen P 1998 Estrogen enhances differentiation of osteoblasts in mouse bone marrow culture. Bone 22:201-209
260. Chow JW, Lean JM, Chambers TJ 1992 17 β-Estradiol stimulates cancellous bone formation in female rats. Endocrinology 130:3025-3032
261. Hughes DE, Dai A, Tiffee JC, Li HH, Mundy GR, Boyce BF 1996 Estrogen promotes apoptosis of murine osteoclasts mediated by TGF-β. Nat Med 2:1132-1136
262. Shevde NK, Bendixen AC, Dienger KM, Pike JW 2000 Estrogens suppress RANK ligand-induced osteoclast differentiation via a stromal cell independent mechanism involving c-Jun repression. Proc Natl Acad Sci USA 97:7829-7834
263. Oursler MJ, Cortese C, Keeting P, Anderson MA, Bonde SK, Riggs BL, Spelsberg TC 1991 Modulation of transforming growth factor-β production in normal human osteoblast-like cells by 17β-estradiol and parathyroid hormone. Endocrinology 129:3313-3320
264. Gao Y, Qian WP, Dark K, Toraldo G, Lin AS, Guldberg RE, Flavell RA, Weitzmann MN, Pacifici R 2004 Estrogen prevents bone loss through transforming growth factor β signaling in T cells. Proc Natl Acad Sci USA 101:16618-16623
265. Cooper MS, Hewison M, StewartPM1999 Glucocorticoid activity, inactivity and the osteoblast. J Endocrinol 163:159-164
266. Lukert BP, Raisz LG 1990 Glucocorticoid-induced osteoporosis: pathogenesis and management. Ann Intern Med 112:352-364
267. Canalis E, Delany AM 2002 Mechanisms of glucocorticoid action in bone. Ann NY Acad Sci 966:73-81
268. Oursler MJ, Riggs BL, Spelsberg TC 1993 Glucocorticoid-induced activation of latent transforming growth factor-β by normal human osteoblast-like cells. Endocrinology 133:2187-2196
269. Centrella M, McCarthy TL, Canalis E 1991 Glucocorticoid regulation of transforming growth factor β 1 activity and binding in osteoblast-enriched cultures from fetal rat bone. Mol Cell Biol 11:4490-4496
270. Chang DJ, Ji C, Kim KK, Casinghino S, McCarthy TL, Centrella M 1998 Reduction in transforming growth factor β receptor I expression and transcription factor CBFa1 on bone cells by glucocorticoid. J Biol Chem 273:4892-4896
271. Takuma A, Kaneda T, Sato T, Ninomiya S, Kumegawa M, Hakeda Y 2003 Dexamethasone enhances osteoclast formation synergistically with transforming growth factor-β by stimulating the priming of osteoclast progenitors for differentiation into osteoclasts. J Biol Chem 278:44667-44674
272. Kawaguchi H, Pilbeam CC, Harrison JR, Raisz LG 1995 The role of prostaglandins in the regulation of bone metabolism. Clin Orthop Relat Res 313:36-46
273. Vrotsos Y, Miller SC, Marks Jr SC 2003 Prostaglandin E-a powerful anabolic agent for generalized or site-specific bone formation. Crit Rev Eukaryot Gene Expr 13:255-263
274. Klein-Nulend J, Semeins CM, Burger EH 1996 Prostaglandin mediated modulation of transforming growth factor-β metabolism in primary mouse osteoblastic cells in vitro. J Cell Physiol 168:1-7
275. Ghayor C, Rey A, Caverzasio J 2005 Prostaglandin-dependent activation of ERK mediates cell proliferation induced by transforming growth factor β in mouse osteoblastic cells. Bone 36:93-100
276. Qin L, Raggatt LJ, Partridge NC 2004 Parathyroid hormone: a double-edged sword for bone metabolism. Trends Endocrinol Metab 15:60-65
277. Sowa H, Kaji H, Iu MF, Tsukamoto T, Sugimoto T, Chihara K 2003 Parathyroid hormone-Smad3 axis exerts anti-apoptotic action and augments anabolic action of transforming growth factor β in osteoblasts. J Biol Chem 278:52240-52252
278. Pfeilschifter J, Laukhuf F, Muller-Beckmann B, Blum WF, Pfister T, Ziegler R 1995 Parathyroid hormone increases the concentration of insulin-like growth factor-I and transforming growth factor β 1 in rat bone. J Clin Invest 96:767-774
279. McCauley LK, Koh AJ, Beecher CA, Cui Y, Decker JD, Franceschi RT 1995 Effects of differentiation and transforming growth factor β 1 on PTH/PTHrP receptor mRNA levels in MC3T3-E1 cells. J Bone Miner Res 10:1243-1255
280. Seitz PK, Zhu BT, Cooper CW 1992 Effect of transforming growth factor β on parathyroid hormone receptor binding and cAMP formation in rat osteosarcoma cells. J Bone Miner Res 7:541-546
281. Kasperk CH, Wergedal JE, Farley JR, Linkhart TA, Turner RT, Baylink DJ 1989 Androgens directly stimulate proliferation of bone cells in vitro. Endocrinology 124:1576-1578
282. Benz DJ, Haussler MR, Thomas MA, Speelman B,KommBS 1991 High-affinity androgen binding and androgenic regulation of α 1(I)-procollagen and transforming growth factor-β steady state messenger ribonucleic acid levels in human osteoblast-like osteosarcoma cells. Endocrinology 128:2723-2730
283. Hofbauer LC, Hicok KC, Khosla S 1998 Effects of gonadal and adrenal androgens in a novel androgen-responsive human osteoblastic cell line. J Cell Biochem 71:96-108
284. Vanderschueren D, Vandenput L, Boonen S, Lindberg MK, Bouillon R, Ohlsson C 2004 Androgens and bone. Endocr Rev 25:389-425
285. Pederson L, Kremer M, Judd J, Pascoe D, Spelsberg TC, Riggs BL, Oursler MJ 1999 Androgens regulate bone resorption activity of isolated osteoclasts in vitro. Proc Natl Acad Sci USA 96:505-510
286. Kasperk C, Fitzsimmons R, Strong D, Mohan S, Jennings J, Wergedal J, Baylink D 1990 Studies of the mechanism by which androgens enhance mitogenesis and differentiation in bone cells. J Clin Endocrinol Metab 71:1322-1329
287. Wu Y, Craig TA, Lutz WH, Kumar R 1999 Identification of 1 α,25-dihydroxyvitamin D3 response elements in the human transforming growth factor β 2 gene. Biochemistry 38:2654-2660
288. 3 synergism toward transforming growth factor-β1-induced AP-1 transcriptional activity in mouse osteoblastic cells via its nuclear receptor. J Biol Chem 273:14738-14744
289. Yanagisawa J, Yanagi Y, Masuhiro Y, Suzawa M, Watanabe M, Kashiwagi K, Toriyabe T, Kawabata M, Miyazono K, Kato S 1999 Convergence of transforming growth factor-β and vitamin D signaling pathways on SMAD transcriptional coactivators. Science 283:1317-1321
290. Nanes MS 2003 Tumor necrosis factor-α: molecular and cellular mechanisms in skeletal pathology. Gene 321:1-15
291. Lovibond AC, Haque SJ, Chambers TJ, Fox SW 2003 TGF-β-induced SOCS3 expression augments TNF-α-induced osteoclast formation. Biochem Biophys Res Commun 309:762-767
292. Verrecchia F, Pessah M, Atfi A, Mauviel A 2000 Tumor necrosis factor-α inhibits transforming growth factor-β/Smad signaling in human dermal fibroblasts via AP-1 activation. J Biol Chem 275:30226-30231
293. Bitzer M, von Gersdorff G, Liang D, Dominguez-Rosales A, Beg AA, Rojkind M, Bottinger EP 2000 A mechanism of suppression of TGF-β/SMAD signaling by NF-κB/RelA. Genes Dev 14:187-197
294. Nagarajan RP, Chen F, Li W, Vig E, Harrington MA, Nakshatri H, Chen Y 2000 Repression of transforming-growth-factor-β-mediated transcription by nuclear factor κB. Biochem J 348:591-596
295. Oursler MJ 1998 Estrogen regulation of gene expression in osteoblasts and osteoclasts. Crit Rev Eukaryot Gene Expr 8:125-140
296. Robinson JA, Harris SA, Riggs BL, Spelsberg TC 1997 Estrogen regulation of human osteoblastic cell proliferation and differentiation. Endocrinology 138:2919-2927
297. Qu Q, Harkonen PL, Monkkonen J, Vaananen HK 1999 Conditioned medium of estrogen-treated osteoblasts inhibits osteoclast maturation and function in vitro. Bone 25:211-215
298. Finkelman RD, Bell NH, Strong DD, Demers LM, Baylink DJ 1992 Ovariectomy selectively reduces the concentration of transforming growth factor β in rat bone: implications for estrogen deficiency-associated bone loss. Proc Natl Acad Sci USA 89:12190-12193
299. Ikeda T, Shigeno C, Kasai R, Kohno H, Ohta S, Okumura H, Konishi J, Yamamuro T 1993 Ovariectomy decreases the mRNA levels of transforming growth factor-β 1 and increases the mRNA levels of osteocalcin in rat bone in vivo. Biochem Biophys Res Commun 194:1228-1233
300. Bord S, Beavan S, Ireland D, Horner A, Compston JE 2001 Mechanisms by which high-dose estrogen therapy produces anabolic skeletal effects in postmenopausal women: role of locally produced growth factors. Bone 29:216-222
301. Matsuda T, Yamamoto T, Muraguchi A, Saatcioglu F 2001 Crosstalk between transforming growth factor-β and estrogen receptor signaling through Smad3. J Biol Chem 276:42908-42914
302. Wu L, Wu Y, Gathings B, Wan M, Li X, Grizzle W, Liu Z, Lu C, Mao Z, Cao X 2003 Smad4 as a transcription corepressor for estrogen receptor α. J Biol Chem 278:15192-15200
303. Shull MM, Ormsby I, Kier AB, Pawlowski S, Diebold RJ, Yin M, Allen R, Sidman C, Proetzel G, Calvin D, Annunziata N, Doetschman T 1992 Targeted disruption of the mouse transforming growth factor-β 1 gene results in multifocal inflammatory disease. Nature 359:693-699
304. Kulkarni AB, Huh CG, Becker D, Geiser A, Lyght M, Flanders KC, Roberts AB, Sporn MB, Ward JM, Karlsson S 1993 Transforming growth factor β 1 null mutation in mice causes excessive inflammatory response and early death. Proc Natl Acad Sci USA 90:770-774
305. Dickson MC, Martin JS, Cousins FM, Kulkarni AB, Karlsson S, Akhurst RJ 1995 Defective haematopoiesis and vasculogenesis in transforming growth factor-β 1 knock out mice. Development 121:1845-1854
306. Geiser AG, Zeng QQ, Sato M, Helvering LM, Hirano T, Turner CH 1998 Decreased bone mass and bone elasticity in mice lacking the transforming growth factor-β1 gene. Bone 23:87-93
307. Sanford LP, Ormsby I, Gittenberger-de Groot AC, Sariola H, Friedman R, Boivin GP, Cardell EL, Doetschman T 1997 TGFβ2 knockout mice have multiple developmental defects that are nonoverlapping with other TGFβ knockout phenotypes. Development 124:2659-2670
308. Proetzel G, Pawlowski SA, Wiles MV, Yin M, Boivin GP, Howles PN, Ding J, Ferguson MW, Doetschman T 1995 Transforming growth factor-β 3 is required for secondary palate fusion. Nat Genet 11:409-414
309. Kaartinen V, Voncken JW, Shuler C, Warburton D, Bu D, Heisterkamp N, Groffen J 1995 Abnormal lung development and cleft palate in mice lacking TGF-β 3 indicates defects of epithelial-mesenchymal interaction. Nat Genet 11:415-421
310. Dabovic B, Chen Y, Colarossi C, Obata H, Zambuto L, Perle MA, Rifkin DB 2002 Bone abnormalities in latent TGF-[beta] binding protein (Ltbp)-3-null mice indicate a role for Ltbp-3 in modulating TGF-[beta] bioavailability. J Cell Biol 156:227-232
311. Sterner-Kock A, Thorey IS, Koli K, Wempe F, Otte J, Bangsow T, Kuhlmeier K, Kirchner T, Jin S, Keski-Oja J, von Melchner H 2002 Disruption of the gene encoding the latent transforming growth factor-β binding protein 4 (LTBP-4) causes abnormal lung development, cardiomyopathy, and colorectal cancer. Genes Dev 16:2264-2273
312. Larsson J, Goumans MJ, Sjostrand LJ, van Rooijen MA, Ward D, Leveen P, Xu X, ten Dijke P, Mummery CL, Karlsson S 2001 Abnormal angiogenesis but intact hematopoietic potential in TGF-β type I receptor-deficient mice. EMBO J 20:1663-1673
313. Oshima M, Oshima H, Taketo MM 1996 TGF-β receptor type II deficiency results in defects of yolk sac hematopoiesis and vasculogenesis. Dev Biol 179:297-302
314. Nomura M, Li E 1998 Smad2 role in mesoderm formation, left-right patterning and craniofacial development. Nature 393:786-790
315. Weinstein M, Yang X, Li C, Xu X, Gotay J, Deng CX 1998 Failure of egg cylinder elongation and mesoderm induction in mouse embryos lacking the tumor suppressor smad2. Proc Natl Acad Sci USA 95:9378-9383
316. Yang X, Letterio JJ, Lechleider RJ, Chen L, Hayman R, Gu H, Roberts AB, Deng C 1999 Targeted disruption of SMAD3 results in impaired mucosal immunity and diminished T cell responsiveness to TGF-β. EMBO J 18:1280-1291
317. Borton AJ, Frederick JP, Datto MB, Wang XF, Weinstein RS 2001 The loss of Smad3 results in a lower rate of bone formation and osteopenia through dysregulation of osteoblast differentiation and apoptosis. J Bone Miner Res 16:1754-1764
318. Datto MB, Frederick JP, Pan L, Borton AJ, Zhuang Y, Wang XF 1999 Targeted disruption of Smad3 reveals an essential role in transforming growth factor β-mediated signal transduction. Mol Cell Biol 19:2495-2504
319. Zhu Y, Richardson JA, Parada LF, Graff JM 1998 Smad3 mutant mice develop metastatic colorectal cancer. Cell 94:703-714
320. Sirard C, de la Pompa JL, Elia A, Itie A, Mirtsos C, Cheung A, Hahn S, Wakeham A, Schwartz L, Kern SE, Rossant J, Mak TW 1998 The tumor suppressor gene Smad4/Dpc4 is required for gastrulation and later for anterior development of the mouse embryo. Genes Dev 12:107-119
321. Yang X, Li C, Xu X, Deng C 1998 The tumor suppressor SMAD4/DPC4 is essential for epiblast proliferation and mesoderm induction in mice. Proc Natl Acad Sci USA 95:3667-3672
322. Atti E, Gomez S, Wahl SM, Mendelsohn R, Paschalis E, Boskey AL 2002 Effects of transforming growth factor-β deficiency on bone development: a Fourier transform-infrared imaging analysis. Bone 31:675-684
323. Dallas SL, Rosser JL, Mundy GR, Bonewald LF 2002 Proteolysis of latent transforming growth factor-β (TGF-β)-binding protein-1 by osteoclasts. A cellular mechanism for release of TGF-β from bone matrix. J Biol Chem 277:21352-21360
324. Baffi MO, Slattery E, Sohn P, Moses HL, Chytil A, Serra R 2004 Conditional deletion of the TGF-β type II receptor in Col2a expressing cells results in defects in the axial skeleton without alterations in chondrocyte differentiation or embryonic development of long bones. Dev Biol 276:124-142
325. Felici A, Wurthner JU, Parks WT, Giam LR, Reiss M, Karpova TS, McNally JG, Roberts AB 2003 TLP, a novel modulator of TGF-β signaling, has opposite effects on Smad2- and Smad3-dependent signaling. EMBO J 22:4465-4477
326. Erlebacher A, Derynck R 1996 Increased expression of TGF-β 2 in osteoblasts results in an osteoporosis-like phenotype. J Cell Biol 132:195-210
327. Filvaroff E, Erlebacher A, Ye J, Gitelman SE, Lotz J, Heillman M, Derynck R 1999 Inhibition of TGF-β receptor signaling in osteoblasts leads to decreased bone remodeling and increased trabecular bone mass. Development 126:4267-4279
328. Erlebacher A, Filvaroff EH, Ye JQ, Derynck R 1998 Osteoblastic responses to TGF-β during bone remodeling. Mol Biol Cell 9:1903-1918
329. Rosen D, Miller SC, DeLeon E, Thompson AY, Bentz H, Mathews M, Adams S 1994 Systemic administration of recombinant transforming growth factor β 2 (rTGF-β 2) stimulates parameters of cancellous bone formation in juvenile and adult rats. Bone 15:355-359
330. Sumner DR, Turner TM, Urban RM, Leven RM, Hawkins M, Nichols EH, McPherson JM, Galante JO 2001 Locally delivered rhTGF-β2 enhances bone ingrowth and bone regeneration at local and remote sites of skeletal injury. J Orthop Res 19:85-94
331. Ohta M, Greenberger JS, Anklesaria P, Bassols A, Massague J 1987 Two forms of transforming growth factor-β distinguished by multipotential haematopoietic progenitor cells. Nature 329:539-541
332. Sparkes RS, Graham CB 1972 Camurati-Engelmann disease. Genetics and clinical manifestations with a review of the literature. J Med Genet 9:73-85
333. Janssens K, Gershoni-Baruch R, Guanabens N, Migone N, Ralston S, Bonduelle M, Lissens W, Van Maldergem L, Vanhoenacker F, Verbruggen L, Van Hul W 2000 Mutations in the gene encoding the latency-associated peptide of TGF-β 1 cause Camurati-Engelmann disease. Nat Genet 26:273-275
334. Kinoshita A, Saito T, Tomita H, Makita Y, Yoshida K, Ghadami M, Yamada K, Kondo S, Ikegawa S, Nishimura G, Fukushima Y, Nakagomi T, Saito H, Sugimoto T, Kamegaya M, Hisa K, Murray JC, Taniguchi N, Niikawa N, Yoshiura K 2000 Domain-specific mutations in TGFB1 result in Camurati-Engelmann disease. Nat Genet 26:19-20
335. Hecht JT, Blanton SH, Broussard S, Scott A, Rhoades Hall C, Milunsky JM 2001 Evidence for locus heterogeneity in the Camurati-Engelmann (DPD1) Syndrome. Clin Genet 59:198-200
336. MummSR, Obrecht S, Podgornik MN, Whyte MP 2001 Camurati-Engelmann disease: new mutations in the latency-associated peptide of the transforming growth factor β-1 gene. J Bone Miner Res 16(Suppl 1):S223
337. Janssens K, ten Dijke P, Ralston SH, Bergmann C, Van Hul W 2003 Transforming growth factor-β 1 mutations in Camurati-Engelmann disease lead to increased signaling by altering either activation or secretion of the mutant protein. J Biol Chem 278:7718-7724
338. Kinoshita A, Fukumaki Y, Shirahama S, Miyahara A, Nishimura G, Haga N, Namba A, Ueda H, Hayashi H, Ikegawa S, Seidel J, Niikawa N, YoshiuraK2004 TGFB1 mutations in four new families with Camurati-Engelmann disease: confirmation of independently arising LAP-domain-specific mutations. Am J Med Genet 127A:104-107
339. McGowan NW, MacPherson H, Janssens K, Van Hul W, Frith JC, Fraser WD, Ralston SH, Helfrich MH 2003 A mutation affecting the latency-associated peptide of TGFβ1 in Camurati-Engelmann disease enhances osteoclast formation in vitro. J Clin Endocrinol Metab 88:3321-3326
340. Oklü R, Hesketh R 2000 The latent transforming growth factor β binding protein (LTBP) family. Biochem J 352:601-610
341. van der Pluijm G, Lowik C, Papapoulos S 2000 Tumour progression and angiogenesis in bone metastasis from breast cancer: new approaches to an old problem. Cancer Treat Rev 26:11-27
342. Guise TA, Yin JJ, Taylor SD, Kumagai Y, Dallas M, Boyce BF, Yoneda T, Mundy GR 1996 Evidence for a causal role of parathyroid hormone-related protein in the pathogenesis of human breast cancer-mediated osteolysis. J Clin Invest 98:1544-1549
343. Guise TA 2000 Molecular mechanisms of osteolytic bone metastases. Cancer 88:2892-2898
344. Derynck R, Akhurst RJ, Balmain A 2001 TGF-β signaling in tumor suppression and cancer progression. Nat Genet 29:117-129
345. Yin JJ, Selander K, Chirgwin JM, Dallas M, Grubbs BG, Wieser R, Massague J, Mundy GR, Guise TA 1999 TGF-β signaling blockade inhibits PTHrP secretion by breast cancer cells and bone metastases development. J Clin Invest 103:197-206
346. Guise TA, Chirgwin JM 2003 Transforming growth factor-β in osteolytic breast cancer bone metastases. Clin Orthop Relat Res (Suppl 415):S32-S38
347. Mercer RR, Miyasaka C, MastroAM2004 Metastatic breast cancer cells suppress osteoblast adhesion and differentiation. Clin Exp Metastasis 21:427-435
348. Mastro AM, Gay CV, Welch DR, Donahue HJ, Jewell J, Mercer R, DiGirolamo D, Chislock EM, Guttridge K 2004 Breast cancer cells induce osteoblast apoptosis: a possible contributor to bone degradation. J Cell Biochem 91:265-276
349. Kang Y, Siegel PM, Shu W, Drobnjak M, Kakonen SM, Cordon-Cardo C, Guise TA, Massague J 2003 A multigenic program mediating breast cancer metastasis to bone. Cancer Cell 3:537-549
350. Yamada Y, Miyauchi A, Takagi Y, Tanaka M, Mizuno M, Harada A 2001 Association of the C-5093→T polymorphism, alone or in combination with the T8693→C polymorphism, of the transforming growth factor-β1 gene with bone mineral density and genetic susceptibility to osteoporosis in Japanese women. J Mol Med 79:149-156
351. Park BL, Han IK, Lee HS, Kim LH, Kim SJ, Shin HD 2003 Identification of novel variants in transforming growth factor-β1 (TGFB1) gene and association analysis with bone mineral density. Hum Mutat 22:257-258
352. Langdahl BL, Carstens M, Stenkjaer L, Eriksen EF 2003 Polymorphisms in the transforming growth factor β 1 gene and osteoporosis. Bone 32:297-310
353. Grainger DJ, Heathcote K, Chiano M, Snieder H, Kemp PR, Metcalfe JC, Carter ND, Spector TD 1999 Genetic control of the circulating concentration of transforming growth factor type β1. Hum Mol Genet 8:93-97
354. Wells FA, Reid DM, Ralston SH 2001 Polymorphisms in the trans-forming growth factor-1 and bone mass and bone loss. Bone 28(Suppl 1):S131
355. Long JR, Liu PY, Lu Y, Dvornyk V, Xiong DH, Zhao LJ, DengHW 2004 Tests of linkage and/or association of TGF-β1 and COL1A1 genes with bone mass. Osteoporos Int 16:86-92
356. Lau HH, Ho AY, Luk KD, Kung AW 2004 Transforming growth factor-β1 gene polymorphisms and bone turnover, bone mineral density and fracture risk in southern Chinese women. Calcif Tissue Int 74:516-521
357. Yamada Y, Miyauchi A, Goto J, Takagi Y, Okuizumi H, Kanematsu M, Hase M, Takai H, Harada A, Ikeda K 1998 Association of a polymorphism of the transforming growth factor-β1 gene with genetic susceptibility to osteoporosis in postmenopausal Japanese women. J Bone Miner Res 13:1569-1576
358. Yamada Y, Harada A, Hosoi T, Miyauchi A, Ikeda K, Ohta H, Shiraki M 2000 Association of transforming growth factor β1 genotype with therapeutic response to active vitamin D for postmenopausal osteoporosis. J Bone Miner Res 15:415-420
359. Hinke V, Seck T, Clanget C, Scheidt-Nave C, Ziegler R, Pfeilschifter J 2001 Association of transforming growth factor-β1 (TGFβ1) T29 → C gene polymorphism with bone mineral density (BMD), changes in BMD, and serum concentrations of TGF-β1 in a population-based sample of postmenopausal German women. Calcif Tissue Int 69:315-320
360. Prince RL, Dick IM, Devine A, Dhaliwal SS, Li S, Wilton S 2002 Effect of the TGF-β T869C and the CYP119 TTTA repeat polymorphisms on bone mineral density and prevalent fracture in elderly women. J Bone Miner Res 17(Suppl 1):S422
361. Dick IM, Devine A, Li S, Dhaliwal SS, Prince RL 2003 The T869C TGF β polymorphism is associated with fracture, bone mineral density, and calcaneal quantitative ultrasound in elderly women. Bone 33:335-341
362. Kim S, Kim H, Hong J, Park J, Kim G 2000 T/C polymorphism of the TGF-β1 gene is not associated with quantitative ultrasound values of calcaneus in Korean postmenopausal women in Chung-Up district. J Bone Miner Res 15(Suppl 1):S362
363. Ziv E, Kahn A, Cauley J, Morin P, Saiz R, Browner W 2003 No association between the TGF-β1 Leu10Pro polymorphism and osteoporosis among white women in the United States. Am J Med 114:227-231
364. Koh JM, Nam-Goong IS, Hong JS, Kim HK, Kim JS, Kim SY, Kim GS 2004 Oestrogen receptor α genotype, and interactions between vitamin D receptor and transforming growth factor-β1 genotypes are associated with quantitative calcaneal ultrasound in postmenopausal women. Clin Endocrinol (Oxf) 60:232-240
365. Langdahl BL, Knudsen JY, Jensen HK, Gregersen N, Eriksen EF 1997 A sequence variation: 713-8delC in the transforming growth factor-β1 gene has higher prevalence in osteoporotic women than in normal women and is associated with very low bone mass in osteoporotic women and increased bone turnover in both osteoporotic and normal women. Bone 20:289-294
366. Bertoldo F, D'Agruma L, Furlan F, Colapietro F, Lorenzi MT, Maiorano N, Iolascon A, Zelante L, Locascio V, Gasparini P 2000 Transforming growth factor-β1 gene polymorphism, bone turnover, and bone mass in Italian postmenopausal women. J Bone Miner Res 15:634-639
367. Keen RW, Snieder H, Molloy H, Daniels J, Chiano M, Gibson F, Fairbairn L, Smith P, MacGregor AJ, Gewert D, Spector TD 2001 Evidence of association and linkage disequilibrium between a novel polymorphism in the transforming growth factor β1 gene and hip bone mineral density: a study of female twins. Rheumatology (Oxf) 40:48-54
368. Dunning AM, Ellis PD, McBride S, Kirschenlohr HL, Healey CS, Kemp PR, Luben RN, Chang-Claude J, Mannermaa A, Kataja V, Pharoah PD, Easton DF, Ponder BA, Metcalfe JC 2003 A transforming growth factorβ1 signal peptide variant increases secretion in vitro and is associated with increased incidence of invasive breast cancer. Cancer Res 63:2610-2615
369. Koh J-M, Kim S-W, Chung Y-E, Hong JS, Kim S-Y, Kim GS 2003 Lack of association of transforming growth factor β 1 T293→C gene polymorphism with calcaneal quantitative ultrasound parameters and plasma TGF-β1 levels in postmenopausal Korean women. Calcif Tissue Int 72(Suppl 1):S418
370. Mundy GR 1991 The effects of TGF-β on bone. Ciba Found Symp 157:137-143; discussion 143-151
371. Terrell TG, Working PK, Chow CP, Green JD 1993 Pathology of recombinant human transforming growth factor-β1 in rats and rabbits. Int Rev Exp Pathol 34(Pt B):43-67
372. Ueda H, Hong L, Yamamoto M, Shigeno K, Inoue M, Toba T, Yoshitani M, Nakamura T, Tabata Y, Shimizu Y 2002 Use of collagen sponge incorporating transforming growth factor-β1 to promote bone repair in skull defects in rabbits. Biomaterials 23:1003-1010
373. Beck LS, Amento EP, Xu Y, Deguzman L, Lee WP, Nguyen T, Gillett NA 1993 TGF-β 1 induces bone closure of skull defects: temporal dynamics of bone formation in defects exposed to rhTGF-β 1. J Bone Miner Res 8:753-761
374. Arnaud E, Morieux C, Wybier M, de Vernejoul MC 1994 Potentiation of transforming growth factor (TGF-β1) by natural coral and fibrin in a rabbit cranioplasty model. Calcif Tissue Int 54:493-498
375. Fujimoto R, Tanizawa T, Nishida S, Yamamoto N, Soshi S, Endo N, Takahashi HE 1999 Local effects of transforming growth factor-β1 on rat calvaria: changes depending on the dose and the injection site. J Bone Miner Metab 17:11-17
376. Tanaka T, Taniguchi Y, Gotoh K, Satoh R, Inazu M, OzawaH1993 Morphological study of recombinant human transforming growth factor β 1-induced intramembranous ossification in neonatal rat parietal bone. Bone 14:117-123
377. Nielsen HM, Andreassen TT, Ledet T, Oxlund H 1994 Local injection of TGF-β increases the strength of tibial fractures in the rat. Acta Orthop Scand 65:37-41
378. Joyce ME, Terek RM, Jingushi S, Bolander ME 1990 Role of transforming growth factor-β in fracture repair. Ann NY Acad Sci 593:107-123
379. Noda M, Camilliere JJ 1989 In vivo stimulation of bone formation by transforming growth factor-β. Endocrinology 124:2991-2994
380. Mackie EJ, Trechsel U 1990 Stimulation of bone formation in vivo by transforming growth factor-β: remodeling of woven bone and lack of inhibition by indomethacin. Bone 11:295-300
381. Marcelli C, Yates AJ, Mundy GR 1990 In vivo effects of human recombinant transforming growth factor β on bone turnover in normal mice. J Bone Miner Res 5:1087-1096
382. Zhou H, Choong PC, Chou ST, Kartsogiannis V, Martin TJ, Ng KW 1995 Transforming growth factor β 1 stimulates bone formation and resorption in an in-vivo model in rabbits. Bone 17(Suppl 4):443S-448S
383. Lind M, Schumacker B, Soballe K, Keller J, Melsen F, Bunger C 1993 Transforming growth factor-β enhances fracture healing in rabbit tibiae. Acta Orthop Scand 64:553-556
384. Vuola J, Bohling T, Goransson H, Puolakkainen P 2002 Transforming growth factor β released from natural coral implant enhances bone growth at calvarium of mature rat. J Biomed Mater Res 59:152-159
385. Bosch C, Melsen B, Gibbons R, Vargervik K 1996 Human recombinant transforming growth factor-β 1 in healing of calvarial bone defects. J Craniofac Surg 7:300-310
386. Shigeno K, Nakamura T, Inoue M, Ueda H, Kobayashi E, Nakahara T, Lynn AK, Toba T, Yoshitani M, Fukuda S, Kawanami R, Shimizu Y 2002 Regenerative repair of the mandible using a collagen sponge containing TGF-β1. Int J Artif Organs 25:1095-1102
387. Ripamonti U, Bosch C, van den Heever B, Duneas N, Melsen B, Ebner R 1996 Limited chondro-osteogenesis by recombinant human transforming growth factor-β 1 in calvarial defects of adult baboons (Papio ursinus). J Bone Miner Res 11:938-945
388. Lind M, Overgaard S, Soballe K, Nguyen T, Ongpipattanakul B, Bunger C 1996 Transforming growth factor-β 1 enhances bone healing to unloaded tricalcium phosphate coated implants: an experimental study in dogs. J Orthop Res 14:343-350
389. Lind M, Overgaard S, Glerup H, Soballe K, Bunger C 2001 Transforming growth factor-β1 adsorbed to tricalciumphosphate coated implants increases peri-implant bone remodeling. Biomaterials 22:189-193
390. Kamakura S, Sasano Y, Nakajo S, Shimizu T, Suzuki O, Katou F, Kagayama M, Motegi K 2001 Implantation of octacalcium phosphate combined with transforming growth factor-β1 enhances bone repair as well as resorption of the implant in rat skull defects. J Biomed Mater Res 57:175-182
391. Sumner DR, Turner TM, Purchio AF, Gombotz WR, Urban RM, Galante JO 1995 Enhancement of bone ingrowth by transforming growth factor-β. J Bone Joint Surg Am 77:1135-1147
392. McKinney L, Hollinger JO 1996 A bone regeneration study: transforming growth factor-β1 and its delivery. J Craniofac Surg 7:36-45
393. Moxham JP, Kibblewhite DJ, Dvorak M, Perey B, Tencer AF, Bruce AG, Strong DM 1996 TGF-β 1 forms functionally normal bone in a segmental sheep tibial diaphyseal defect. J Otolaryngol 25:388-392
394. Gombotz WR, Pankey SC, Bouchard LS, Phan DH, Puolakkainen PA 1994 Stimulation of bone healing by transforming growth factor-β1 released from polymeric or ceramic implants. J Appl Biomater 5:141-150
395. Schmidmaier G, Wildemann B, Heeger J, Gabelein T, Flyvbjerg A, Bail HJ, Raschke M 2002 Improvement of fracture healing by systemic administration of growth hormone and local application of insulin-like growth factor-1 and transforming growth factor-β1. Bone 31:165-172
396. Heckman JD, Ehler W, Brooks BP, Aufdemorte TB, Lohmann CH, Morgan T, Boyan BD 1999 Bone morphogenetic protein but not transforming growth factor-β enhances bone formation in canine diaphyseal nonunions implanted with a biodegradable composite polymer. J Bone Joint Surg Am 81:1717-1729
397. Aspenberg P, Jeppsson C, Wang JS, Bostrom M 1996 Transforming growth factor β and bone morphogenetic protein 2 for bone ingrowth: a comparison using bone chambers in rats. Bone 19:499-503
398. Tieline L, Puolakkainen P, Pohjonen T, Rautavuori J, Tormala P, Rokkanen P 2002 The effect of transforming growth factor-β1, released from a bioabsorbable self-reinforced polylactide pin, on a bone defect. Biomaterials 23:3817-3823
399. Schmitt JM, Buck D, Bennett S, Skalla W, Christoforou C, Buechter D, Gruskin E, Hollinger J 1998 Assessment of an experimental bone wax polymer plus TGF-β 1 implanted into calvarial defects. J Biomed Mater Res 41:584-592
400. Hong L, Tabata Y, Miyamoto S, Yamada K, Aoyama I, Tamura M, Hashimoto N, Ikada Y 2000 Promoted bone healing at a rabbit skull gap between autologous bone fragment and the surrounding intact bone with biodegradable microspheres containing transforming growth factor-β1. Tissue Eng 6:331-340
401. Aufdemorte TB, Fox WC, Holt GR, McGuff HS, Ammann AJ, Beck LS 1992 An intraosseous device for studies of bone-healing. The effect of transforming growth-factor β. J Bone Joint Surg Am 74:1153-1161
402. Mehrara BJ, Saadeh PB, Steinbrech DS, Dudziak M, Spector JA, Greenwald JA, Gittes GK, Longaker MT 1999 Adenovirus-mediated gene therapy of osteoblasts in vitro and in vivo. J Bone Miner Res 14:1290-1301
403. Geesink RG, Hoefnagels NH, Bulstra SK 1999 Osteogenic activity of OP-1 bone morphogenetic protein (BMP-7) in a human fibular defect. J Bone Joint Surg Br 81:710-718
404. Friedlaender GE, Perry CR, Cole JD, Cook SD, Cierny G, Muschler GF, Zych GA, Calhoun JH, LaForte AJ, Yin S 2001 Osteogenic protein-1 (bone morphogenetic protein-7) in the treatment of tibial nonunions. J Bone Joint Surg Am 83-A (Suppl 1):S151-S158
405. Govender S, Csimma C, Genant HK, Valentin-Opran A, Amit Y, Arbel R, Aro H, Atar D, Bishay M, Borner MG, Chiron P, Choong P, Cinats J, Courtenay B, Feibel R, Geulette B, Gravel C, Haas N, Raschke M, Hammacher E, van der Velde D, Hardy P, Holt M, Josten C, Ketterl RL, Lindeque B, Lob G, Mathevon H, McCoy G, Marsh D, Miller R, Munting E, Oevre S, Nordsletten L, Patel A, Pohl A, Rennie W, Reynders P, Rommens PM, Rondia J, Rossouw WC, Daneel PJ, Ruff S, Ruter A, Santavirta S, Schildhauer TA, Gekle C, Schnettler R, Segal D, Seiler H, Snowdowne RB, Stapert J, Taglang G, Verdonk R, Vogels L, Weckbach A, Wentzensen A, Wisniewski T 2002 Recombinant human bone morphogenetic protein-2 for treatment of open tibial fractures: a prospective, controlled, randomized study of four hundred and fifty patients. J Bone Joint Surg Am 84-A:2123-2134
406. Raisz LG 1999 Osteoporosis: current approaches and future prospects in diagnosis, pathogenesis, and management. J Bone Miner Metab 17:79-89
407. Rosen CJ, Bilezikian JP 2001 Clinical review 123: Anabolic therapy for osteoporosis. J Clin Endocrinol Metab 86:957-964
408. Attisano L, Lee-Hoeflich ST 2001 The Smads. Genome Biology 2:REVIEWS3010
409. Yeo CY, Chen X, Whitman M 1997 The role of FAST-1 and Smads in transcriptional regulation by activin during early Xenopus embryogenesis. J Biol Chem 274:26584-26590